Bayer-JPM-2023.pdf

1、J.P.Morgan HealthcareConference41st AnnualJanuary 10,2023Stefan OelrichMember of the Board of Management of Bayer AGPresident PharmaceuticalsDriving our strategic agenda2/41st Annual J.P.Morgan Healthcare Conference/Bayer PharmaceuticalsGrow potential blockbustersCapture the full commercial value of

2、 the current portfolio1Renew toplineBuild&grow US businessShift in marketing&R&D towards growth driversReallocate resources2Progress late-stage pipelineStrengthen early pipelinethrough increasing contributions from platform companies as well as partneringRebuild pipeline3Investing in future growth w

3、hile managing our P&Lalong the projected trajectory/41st Annual J.P.Morgan Healthcare Conference/Bayer PharmaceuticalsEBITDA margin*(cpa*)Balance LoEs&drive late-stage pipelineReturn to above average growthSales Growth(cpa*)2023e-2026e 2027e10yrs average:32%Label expansions,guideline inclusions&cont

4、inued rollouts of Nubeqa and KerendiaCompetitive profile of key assets further strengthenedBuild-up of US organization completedStrong LCM newsflow,Asundexian moved into PIIIContinued pipeline pruning and advancements of new gene therapies into Phase I9M 2022*EBITDA before special items,cpa=currency

5、 and portfolio adjusted;LCM:Lifecycle management;LoE:Loss of exclusivity 3 3In 9M 2022 we have absorbed significant headwinds that emerged during the year4/41st Annual J.P.Morgan Healthcare Conference/Bayer PharmaceuticalsSalesPrice pressure EuropeChina:VBP and COVID lockdownsEBITDA*marginLower sale

6、sCost increases in raw materialsAdverse FX impactsImpact on Bayer Pharmaceuticals in 9M 2022reported30.8%+8%War in UkraineInflationSupply chain disruptionsNegative market dynamics,e.g.COVID-19(China)EUR devaluationLimited or no ability to react on increasing COGS Reimbursement&pricing pressure acros